Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overview of CDK9 as a target in cancer research

15 Jan 2016

Abstract excerpt

CDK9 is a protein in constant development in cancer therapy. Herein we present an overview of the enzyme as a target for cancer therapy. We provide data on its characteristics and mechanism of action. In recent years, CDK9 inhibitors that have been designed with molecular modeling have demonstrated good antitumoral activity in vitro. Clinical studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26766294
DOI: 10.1080/15384101.2016.1138186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overview of CDK9 as a target in cancer researchPMID 26766294Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Targeting CDK9 for Anti-Cancer TherapeuticsSemantic proximity Read ↗

CDK9 as an Appealing Target for Therapeutic InterventionsSemantic proximity Read ↗

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug TargetSemantic proximity Read ↗

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Semantic proximity Read ↗

An overview of CDK3 in cancer: clinical significance and pharmacological implicationsSemantic proximity Read ↗

CDK9: A key player in cancer and other diseasesSemantic proximity Read ↗

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An UpdateSemantic proximity Read ↗

Deregulations in the Cyclin-Dependent Kinase-9-Related Pathway in Cancer: Implications for Drug Discovery and DevelopmentSemantic proximity Read ↗

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read ↗

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read ↗

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.